Jubilant Life Sciences, an integrated Pharmaceuticals and Life Sciences Company has received a communication from the US Food and Drug Administration (USFDA), classifying its pharmaceutical manufacturing facility at Montreal, Canada as ‘Acceptable’. This resolves all issues raised by the USFDA on the facility in February 2013 and subsequent communications.
The development follows completion of FDA’s review of the company’s responses post the February letter and the subsequent re-inspection conducted at Jubilant’s Montreal facility in September, 2013. This development successfully resolves the FDA issues at our Montreal facility.
Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
